|Host Cells||HEK293 cells|
|MW||50 and 25 kDa for the heavy and light chains, respectively (150 kDa)|
|Isotype||Human IgG1, Kappa LC|
Neutralizing recombinant human antibody recognizes the extracellular domain of human PD-L1 and blocks the binding of PD-L1 to PD-1. This antibody has not been tested for cross-reactivity with other species.
IC50 = 3.75 nM using the PD-1[Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. # EP-101).
Protein A affinity chromatography from HEK293 supernatants.
Less than 0.05 EU per μg by the LAL method.
Useful as a control inhibitor of PD-L1 binding using the PD-1[Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. # EP-101)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product form or formulation.
See Certificate of Analysis for reconstitution instructions and specific concentrations.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
4 ℃ for 1 year in lyophilized state.
-70 ℃ for 3 months under sterile conditions after reconstitution.
Inhibition of PD-1-PD-L1 binding by Anti-PD-L1 (CD274) Neutralizing Antibody (Catalog # PDL-NA002) measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Catalog # EP-101)
Anti-PD-L1 (CD274) neutralizing antibody (Cat. # PDL-NA002) was diluted from 20 ug/ml to 0.027 ug/ml and loaded onto the plate coated by human PD-L1 protein in the presence of biotinylated human PD-1 protein. Background was subtracted from data points prior to log transformation and curve fitting.
Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1). Immune checkpoint pathway is a focal point of today’s cancer research. PD-L1 is one of the best characterized checkpoint proteins. The binding between PD-L1 and its receptor PD1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-L1 or its receptor has been considered a promising strategy by many oncologists. The anti-PD-L1 (CD274) neutralizing antibody developed by ACRObiosystems specifically recognizes the extracellular domain of human PD-L1 and blocks the binding of PD-L1 to PD-1, and is very useful as positive control in inhibition assays.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.